Share this article
Share this article
LUND, Sweden, Feb. 15, 2021 /PRNewswire/ According to the American Cancer Society, as many as 10% of pancreatic cancers are caused by familial and hereditary risk factors. PanFAM-1 is the largest prospective study to date, focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC). Designed to support the road to reimbursement for Immunovia s blood test, IMMray™ PanCan-d, the study has ended enrollment of new subjects October 30, 2020 from the 23 familial/hereditary pancreatic cancer high-risk surveillance programs in USA and Europe. The study reports the collection of over 3000 blood samples from 1265 subjects. The last blood samples will be collected in April 2021. All blood samples will be analysed in the second half of 2021.
Share this article
LUND, Sweden, Feb. 10, 2021 /PRNewswire/
Immunovia AB (publ) ( Immunovia ) today provides an update on the status of the company s activities and as previously reported (Webinar Dec 17, 2020
), Immunovia will initiate sales start in Q1 2021 of the company s first test, IMMray™ PanCan-d designed for early detection of pancreatic cancer.
Since the last update, Immunovia s R&D and production departments in Lund have been working at full speed to ensure the highest quality reagents and arrays are available for the final blind validation study of IMMray™ PanCan-d. All the necessary samples for the blind validation study have been secured and will be analyzed in Marlborough in Q1.
I
mmunovia AB, ( Immunovia ) a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced results from a study in their development pipeline, published in the peer-reviewed Journal of Proteome Research. These are the first proteomic data allowing a differential analysis of four different inflammatory rheumatic diseases (IRDs).
Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms. The aim of the study was to achieve protein expression profiles distinguishing four systemic IRDs, that if left untreated, can lead to severe and sometimes permanent disability, increased morbidity, and premature mortality. A total of 316 serum samples collected from patients with Systemic Lupus Erythematosus (SLE), ANCA associated systemic vasculitis (SV), Rheumatoid Arthritis (RA) and Sjögren s Syndrome (SS), and healthy controls were analysed, using Im
Proteomic data derived from Immunovia s IMMray-platform allows differential diagnosis of difficult to distinguish autoimmune diseases
I
mmunovia AB, ( Immunovia ) a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced results from a study in their development pipeline, published in the peer-reviewed Journal of Proteome Research. These are the first proteomic data allowing a differential analysis of four different inflammatory rheumatic diseases (IRDs).
Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms. The aim of the study was to achieve protein expression profiles distinguishing four systemic IRDs, that if left untreated, can lead to severe and sometimes permanent disability, increased morbidity, and premature mortality. A total of 316 serum samples collected from patients with Systemic Lupus Erythematosus (SLE), ANCA ass
Immunovia publishes link to Webinar No. 3 on IMMray PanCan-d: Verification Study and Clinical Use
LUND, Sweden, Dec. 14, 2020 /PRNewswire/ Immunovia AB (publ) ( Immunovia ) today published the link to the company s third webinar in a series on IMMray PanCan-d, Immunovia s test for early detection of pancreatic cancer. The webinar will cover the IMMray PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases.
Event Details:
Date and Time: December 17, 2020 at 15:00 CET
Moderator for the webinar: CEO Patrik Dahlen
Presenters: Thomas King, MD, PhD; Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia